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Abstract
Motivation: We introduce TRONCO (TRanslational ONCOlogy), an open-source R package
that implements the state-of-the-art algorithms for the inference of cancer progression models
from (epi)genomic mutational profiles. TRONCO can be used to extract population-level models
describing the trends of accumulation of alterations in a cohort of cross-sectional samples,
e.g., retrieved from publicly available databases, and individual-level models that reveal the
clonal evolutionary history in single cancer patients, when multiple samples, e.g., multiple
biopsies or single-cell sequencing data, are available. The resulting models can provide key
hints in uncovering the evolutionary trajectories of cancer, especially for precision medicine or
personalized therapy.
Availability: TRONCO is released under the GPL license, it is hosted in the Software section
at http://bimib.disco.unimib.it/ and archived also at bioconductor.org.
Contact: tronco@disco.unimib.it
1 Introduction
Cancer develops through the successive expansions of clones, in which certain (epi)genomic al-
terations, called drivers, confer a fitness advantage and progressively accumulate, in a context of
overall scarcity of resources [6]. Specifically, in Nowell’s seminal work, tumor evolution is described
in terms of stepwise genetic variation such that growth advantage is the key for the survival and pro-
rogation of the clones. Therefore, one can define cancer progression models, in terms of probabilistic
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Figure 1: (A) TRONCO can process either alterations (e.g., somatic mutations or wider chromosomal
lesions) in a cohort of independent samples (top lolliplot diagram), or a set of multiple snapshots
from a unique patient (e.g., multi-region or single-cell, bottom panel). (B) Oncoprints allow the
user to visualize the data that the tool is processing. Regardless of the source, each row represents
a certain alteration - at a custom resolution depending on the cancer under study - and each
column a sample. (C) A model inferred with the tool might outline cancer evolution occurring
in a population ensemble or in an individual patient. Graphically, alterations are represented as
nodes with different colors (e.g., green mutations and blue homozygous deletions). Algorithms
such as CAPRI allow describing alterations with logical formulas, in an attempt to find their role
as a “group” (see [8] for details); we picture such groups with dashed lines. In the panel, we
show a hypothetical ensemble-level model predicting a selection pressure on two genes mapped to
17p13, tp53 and hic1, as it may be inferred by analyzing samples harbouring either tp53/hic1
mutations or homozygous deletions in the cytoband where any of these two genes map, i.e., here
for purely explanatory cases we suppose just tp53, which maps to 17p13.1. The model suggests a
trend of selection towards mutations in gene y, which shall be interpreted as a set of preferential
clonal expansions characteristic of the population of analyzed samples, involving alterations of the
functions mapped to 17p13 and y. (D) TRONCO supports three data types. Custom data, which
is supposed to be provided as a binary input matrix storing the presence (1) or absence (0) of a
certain alteration in a sample. Or, standard data formats such as the Mutation Annotation Format
(MAF) for somatic mutations, as well as the Genomic Identification of Significant Targets in Cancer
(GISTIC) format for focal Copy Number Variations. Data can be generated by custom experiments,
or collected - along with other “omics” - from public databases such as TCGA and cBio portal. For
the latter, cBio portal, TRONCO implements a query system to fetch data with minimal effort. The
tool engine can then be used to manipulate genomic profiles – regardless of their source – and run
progression inference algorithms.
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causal graphical models, where the conditional dependencies and the temporal ordering among these
alterations are described, revealing the evolutionary trajectories of cancer at the (epi)genome level.
We further distinguish [3]. (i) ensemble-level progression models, describing the statistical
trends of accumulation of genomic alterations in a cohort of distinct cancer patients. Such models
describe the temporal partial orders of fixation and accumulation of such alterations and represent
population-level trends; and (ii) individual-level models, thus accounting for the specific evolution-
ary history of cancer clones in individual tumors. Such models thus impute the ancestry relations
of the observed clones.
Even if the inference of such models is further complicated by a series of theoretical and technical
hurdles, such as, e.g., intra- and inter-tumor heterogeneity and the effective detection of drivers,
it can benefit from the increasing amount of next-generation sequencing (NGS) data, currently
available through public projects such as The Cancer Genome Atlas (TCGA, https://tcga-data.
nci.nih.gov). Usually, such databases provide cross-sectional (epi)genomic profiles retrieved from
single biopsies of cancer patients, which can be used to extract ensemble-level models; but higher
resolution data such as multiple-biopsies, or even single-cell sequencing data are becoming more
accessible and reliable, which can be used to infer individual-level models.
Here we introduce TRONCO (TRanslational ONCOlogy), an R package built to infer cancer pro-
gression models from heterogeneous genomic data (in the form of alterations persistently present
along tumor evolution.) Currently, TRONCO provides the implementation of two algorithms: (i)
CAPRESE (CAncer PRogression Extraction with Single Edges [7]), and (ii) CAPRI (CAncer PRogres-
sion Inference [8]), both based on Suppes’ theory of probabilistic causation [9], but with distinct
goals and properties (see Software Implementation).
TRONCO, in its current form and perspective, should be thought of as a tool that provides the
implementation of up-to-date solutions to the progression inference problem. At the time of the
writing it can be effectively used as the final stage of a modular pipeline for the extraction of
ensemble-level cancer progression models from cross-sectional data [3]. In such a pipeline input data
are pre-processed to (i) stratify samples in tumor subtypes, (ii) select driver alterations and (iii)
identify groups of fitness-equivalent (i.e., mutually exclusive) alterations, prior to the application
of the CAPRI algorithm. The resulting ensemble-level progression models depict the evolutionary
dynamics of cancer, with translational impacts on diagnostic and therapeutic processes, especially
in regard to precision medicine and personalized drug development.
From the complementary perspective, TRONCO can also exploit the CAPRESE algorithm to infer
the clonal evolutionary history in single patients when multiple samples are available, as in the case
of multiple biopsies and/or single-cell sequencing data, as long as the set of driver events is selected;
see [3].
2 Software Implementation
TRONCO implements a set of R functions to aid the user to extract a cancer progression model
from genomic data. At a high-level, these function shall help to import, visualize and manipulate
genomic profiles – regardless of their source – eventually allowing the implemented algorithms to
run and assess the confidence in a model.
The basics steps of TRONCO’s usage are shown in Figure 1. In panel (a) we show multiple input
alterations (e.g., somatic mutations or copy number alterations) either from a cohort of patients,
or a unique patient (e.g., multi-region or single-cell sequencing); in panel (b) we show an oncoprint
visualization from the tool, i.e., a matrix whose columns represent samples and rows the alterations
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and their presence per sample; panel (c) shows an inferred graphical Bayesian progression model
obtained with one of the available algorithms; finally, in panel (d) we show data supported for
processing in the tool. For a more detailed explanation of the implementation of the package see
[1].
Data loading and manipulation. Common formats to store data used to extract progression
models can be natively imported. These include, for instance, the Mutation Annotation Format
(MAF) for somatic mutations, as well as the Genomic Identification of Significant Targets in Cancer
(GISTIC) format to store focal Copy Number Variations. The tool can exploit the cBio portal for
Cancer Genomics, which collects among others TCGA projects, to access freely available instances
of such data [4].
TRONCO provides functions for data preprocessing to, e.g., select a certain subset of alterations,
or samples or any abstraction which might be appropriate according to the cancer being studied.
Visualization and interaction with other tools. TRONCO implements an oncoprint system
to visualize the processed data. Datasets can be exported for processing by other tools used to,
e.g., stratify input samples and detect groups of mutually exclusive alterations, which include the
Network Based Stratification [5] and MUTEX [2] tools. TRONCO allows the visualization of the
inferred models.
Model inference and confidence. TRONCO provides two algorithms: (i) CAPRESE, which uses
a shrinkage-like estimator to infer tree-models of progression, and (ii) CAPRI, which extracts more
general direct acyclic graphs (DAG) - thus allowing for confluent evolution and complex hypothesis
testing – by combining bootstrap and maximum likelihood estimation. CAPRESE and CAPRI both
rely on the same theory of probabilistic causation, but with distinct goals and properties. The
former reconstructs tree models of progressions, while the latter general directed acyclic graphs.
Both methods are agnostic to the type of input data (i.e., whether its an ensemble or an individual
tumor), but shall be used in different contexts as they produce different types of models. Indeed,
CAPRESE is better at extracting cancer evolution in a single individual as in that case trees capture
branched evolution and trunk events, which shall suffice to describe clonal evolution. Instead, when
heterogeneity might result in multiple evolutionary routes with common downstream alterations,
the underlying true model is a graph, and CAPRI should be the tool of choice.
Whatever a model is, TRONCO implements a set of functions to assess its confidence via (i)
non-parametric, (ii) parametric and (iii) statistical bootstrap.
3 Discussion
TRONCO provides up-to-date, theoretically well-founded, statistical methods to understand the evo-
lution of a cancer (ensamble-level) or a single tumor (individual-level). The implemented algorithms
are demonstrably the state-of-the-art for the progression inference problem, in terms of computa-
tional cost, scalability with respect to sample size, accuracy and robustness against noise in the
data. The implementation makes straightforward the interaction of TRONCO with other common
bioinformatics tools, possibly allowing the creation of a common suite of tools for cancer progression
inference.
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Finally, we refer to [3] or the Supplementaty materials for a demonstration of the usage of
TRONCO on real genomics data both at the ensemble-level and individual-level progression models.
In particular, this paper outlines the capability of the methods to reproduce much of the current
knowledge on the progression for a set of cancer types, as well as to suggest clinically relevant
insights. Furthermore, we also provide users with detailed manuals, vignettes, and source code to
replicate all the analysis presented in the paper plus others (case studies: colorectal cancer, clear
cell renal cell carcinoma and acute chronic myeloid leukaemia) in the Supplementary Materials and
at the TRONCO official webpage (Software section at http://bimib.disco.unimib.it/).
Financial support. MA, GM, GC, AG, DR acknowledge Regione Lombardia (Italy) for the re-
search projects RetroNet through the ASTIL Program [12-4-5148000-40]; U.A 053 and Network
Enabled Drug Design project [ID14546A Rif SAL-7], Fondo Accordi Istituzionali 2009. BM ac-
knowledges founding by the NSF grants CCF-0836649, CCF-0926166 and a NCI-PSOC grant.
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1 Installation
TRONCO’s current stable release is version 2.0 (Mantish Shrimp, August 2015).
This can be installed from our GitHub account by typing within R the
following commands:
> library(devtools)
> install_github("BIMIB-DISCo/TRONCO")
Mantis Shrimp is also in Bioconductor 3.2 since 14 October 2015.
2 Examples
TRONCO official webpage (http://bimib.disco.unimib.it/) hosts detail com-
mentary and source code to replicate the following studies:
1. Atypical Chronic Myeloid Leukemia (aCML) - ensemble level;
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2. Colorectal Cancer (CRC) - ensemble level;
3. Clear Cell Renal Cell Carcinoma (CCRCC) - individual level;
4. Single-cell synthetic data test for reconstruction’s performance;
5. Processing data from the cBio portal (next section)
In the next subsections we present a few examples of usage of the tool.
2.1 Fetching data from the cBio portal
We show how to download lung cancer data of somatic mutations reported in
Figure 1(a) of the paper
Comprehensive molecular profiling of lung adenocarcinoma. The TCGA
Consortium. Nature 511, 543-550, 2014.
from the archives available at cBio portal under url
http://www.cbioportal.org/study.do?cancer_study_id=luad_tcga_pub
The code that we show is tested under R’s most recent version.
Fetching data. First, define the pool of genes for which one wishes to down-
load data. In this case we have a list of 18 genes from the reference figure.
> genes = c(’TP53’, ’KRAS’, ’KEAP11’, ’STK11’, ’EGFR’, ’NF1’,
> ’BRAF’, ’SETD2’, ’RBM10’, ’MGA’, ’MET’, ’ARID1A’, ’PIK3CA’,
> ’SMARCA4’, ’RB1’, ’CDKN2A’, ’U2AF1’, ’RIT1’)
Data in cBio portal are identified by the following triple:
• a study ID - a high-level references of the study, here luad tcga pub;
• a dataset ID - a set of samples which are part of the study, in our case
luad tcga pub cnaseq;
• a genetic profile ID - a type of data available for those samples, here
luad tcga pub mutations.
With these references, one can extract data from the portal. If these are not
known in advance, one can run TRONCO’s function cbio.query which wraps
the CGDS-R package - the official query system for the portal, in R.
This function will help you by showing the available data at the portal:
> data = cbio.query(genes=genes)
*** CGDS plugin for cBio portal query.
Available studies at cBio portal.
2
cancer_study_id name
[ ... ]
45 luad_broad Lung Adenocarcinoma (Broad, Cell 2012)
46 luad_tcga_pub Lung Adenocarcinoma (TCGA, Nature 2014)
47 luad_tcga Lung Adenocarcinoma (TCGA, Provisional)
[ ... ]
> Enter cBio study id: luad_tcga_pub
Here from a list of IDs archived at the portal, and we have selected the one
which references the data used in the manuscript. Notice that the user can
also access provisional TCGA data or datasets from other studies such as those
carried out at the Broad Institute of MIT and Harvard.
The function cbio.query will then load dataset information and will allow
the user to select the set of desired samples, in this case we select all tumor
samples that have CNA and sequencing data.
> Cancer codename: luad_tcga_pub
Cancer Ref.: Lung Adenocarcinoma (TCGA, Nature 2014)
Cancer Syn.: TCGA Lung Adenocarcinoma, containing 230 samples;
Available datasets for study: luad_tcga_pub
case_list_id case_list_description
1 luad_tcga_pub_3way_complete All tumor samples that have
mRNA, CNA and sequencing data
(230 samples)
[ ... ]
22 luad_tcga_pub_cnaseq All tumor samples that have CNA
and sequencing data
(230 samples)
> Enter study dataset id: luad_tcga_pub_cnaseq
Which opens a view over the available genetic profiles for the selected 230
samples.
Data codename: luad_tcga_pub_cnaseq
Data Ref.: Tumors with sequencing and CNA data
Data Syn.: All tumor samples that have CNA and sequencing data
(230 samples)
Available genetic profiles for selected datasets.
genetic_profile_id genetic_profile_description
1 luad_tcga_pub_rna_seq_v2 mRNA z-Scores ...
mrna_median_Zscores
[ ... ]
4 luad_tcga_pub_gistic Putative copy-number calls on
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230 cases GISTIC 2.0.
[ ... ]
6 luad_tcga_pub_methylation_hm27 Methylation (HM27) beta-val ...
8 luad_tcga_pub_mutations Mutation data from WES.
[ ... ]
11 luad_tcga_pub_mrna Expression levels for 17235 ...
> Enter genetic profile id: luad_tcga_pub_mutations
If we wish to select other type of data for these samples we just re-run
this script and select, e.g., mRNA z-Scores, expression values or Methylation
beta-values.
Samples codename: luad_tcga_pub_mutations
Data Ref.: Mutations
Data Syn.: Mutation data from whole exome sequencing.
Querying the following list of genes: TP53, KRAS, ......, RIT1
Symbol "." was replaced with "-" in sample IDs.
Data retrieved: 230 samples, 17 genes.
Retrieved also clinical data for samples: luad_tcga_pub_cnaseq
Data exported to file: luad_tcga_pub.luad_tcga_pub_cnaseq.luad_tcga
In this way we collected 230 samples and 5 genes, plus the function auto-
matically downloads clinical data for the selected samples. All these data are
exported to an Rdata file named for this query
luad tcga pub.luad tcga pub cnaseq.luad tcga pub mutations.Rdata
so that further processing can happen offline.
From data to a TRONCO object. The returned object, here data, has
flags to access the retrieved data. Mutation data is available through $profile
tag, clinical data through $clinical tag.
> head(data$profile[, 1:5])
ARID1A BRAF CDKN2A EGFR KRAS
TCGA-05-4249-01 NaN A762E NaN NaN G12C
TCGA-05-4382-01 E1760* L613F NaN R222L,E545Q NaN
TCGA-05-4384-01 NaN NaN NaN NaN NaN
TCGA-05-4389-01 NaN G469V NaN NaN NaN
TCGA-05-4390-01 NaN NaN NaN NaN G12V
TCGA-05-4395-01 NaN NaN NaN NaN G12V
> head(data$clinical[, ’HISTOLOGICAL_SUBTYPE’, drop = F])
HISTOLOGICAL_SUBTYPE
TCGA-55-7573-01 Lung Adenocarcinoma- Not Otherwise Specified (NOS)
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TCGA-78-7150-01 Lung Adenocarcinoma- Not Otherwise Specified (NOS)
TCGA-55-7727-01 Lung Adenocarcinoma- Not Otherwise Specified (NOS)
TCGA-49-6767-01 Lung Adenocarcinoma- Not Otherwise Specified (NOS)
TCGA-49-6744-01 Lung Adenocarcinoma Mixed Subtype
TCGA-49-4488-01 Lung Adenocarcinoma- Not Otherwise Specified (NOS)
Basic conversion to this format to a representation which can be imported
with TRONCO is straightforward, as we can go through a conversion to R’s
matrix, replace string values with corresponding 0s and 1s - as in this case we
are not distinguishing types of mutations - , and transform the matrix in a
tronco object via import.genotypes.
The imported dataset can be seen in the console with show, and visualized
via oncoprint.
> m = as.matrix(data$profile)
> m[is.na(m)] = 0
> m[m == ’NaN’] = 0
> m[m != ’0’] = 1
> tronco.data = import.genotypes(m, event.type = ’Mutation’,
> color = ’brown3’)
> tronco.data = annotate.description(tronco.data,
> "Lung cancer data from cBio portal")
> show(tronco.data, 5)
Description: Lung cancer data from cBio portal.
Dataset: n=230, m=17, |G|=17.
Events (types): Mutation.
Colors (plot): brown3.
Events (10 shown):
G1 : Mutation ARID1A
G2 : Mutation BRAF
G3 : Mutation CDKN2A
G4 : Mutation EGFR
G5 : Mutation KRAS
Genotypes (10 shown):
G1 G2 G3 G4 G5
TCGA-05-4249-01 0 1 0 0 1
TCGA-05-4382-01 1 1 0 1 0
TCGA-05-4384-01 0 0 0 0 0
TCGA-05-4389-01 0 1 0 0 0
TCGA-05-4390-01 0 0 0 0 1
TCGA-05-4395-01 0 0 0 0 1
> oncoprint(tronco.data)
*** Oncoprint for "Lung cancer data from cBio portal"
with attributes: stage=FALSE, hits=TRUE
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Sorting samples ordering to enhance exclusivity patterns.
Setting automatic row font (exponential scaling): 10.7
The image obtained is shown in figure 1.
Lung cancer data from Cbio portal
46% TP53
33% KRAS
17% STK11
14% EGFR
11% NF1
10% BRAF
9% SETD2
8% MET
8% MGA
8% RBM10
7% ARID1A
7% PIK3CA
6% SMARCA4
4% RB1
4% CDKN2A
3% U2AF1
2% RIT1
hits hits
5
0
none
Mutation
230 samples
17 events
17 genes
0 patterns
Figure 1: Oncoprint showing the genomic profiles obtained by quering cBio
portal.
The reconstruction of a progression model is straightforward. For instance,
to use CAPRI algorithm - with its default settings - and set a few graphical
parameters to scale nodes size as of events’ frequencies, scale legend which gets
displayed in top corners and show p-values for the two elements which constitute
the statistical evidence of selective advantage (temporal priority and probability
raising) and hypergeometric test.
> tronco.plot(
> tronco.capri(tronco.data),
> scale.nodes = .6,
> legend.cex = .6,
> legend.pos = ’top’,
> confidence = c(’tp’, ’pr’, ’hg’))
In a similar way, one might download, e.g., GISTIC data for CNAs, merge
it to these mutations - via TRONCO’s functions - and build a model with both
data types included.
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2.2 Clonal architecture of Clear Cell Renal Cell Carci-
noma (CCRCC)
We now adopt the public data from Gerlinger et al., Nat Gen 46, 2014 to show
that the presented algorithms can be used to successfully reconstruct the clonal
architecture in individual patients. We consider data coming from multi-region
targeted exome-sequencing with high coverage (> 70x), which are reported in
the reference paper as figures and in the supplementary materials.
Text files of the genetic profiles provided in such supplementary resources
have been given as input to TRONCO and imported with the following R func-
tion (i.e., import.sample).
# Import data - this converts the data from the CSV text file
# obtained from Excel, to a TRONCO object
import.sample = function(filename) {
data = as.matrix(read.csv(paste0(filename), header=F))
curr.data = NULL
curr.data$genotypes = apply(data[c(-1,-2), -1, drop=F],
2, as.numeric)
rownames(curr.data$genotypes) = data[c(-1,-2),1]
curr.data$annotations = matrix(c(data[2, -1], data[1, -1]),
ncol=2)
event.names = c()
for(i in 1:nrow(curr.data$annotations)){
event.names = c(event.names, paste0("G",i))
}
colnames(curr.data$genotypes) = event.names
rownames(curr.data$annotations) = event.names
colnames(curr.data$annotations) = c("type", "event")
curr.data$types = matrix(’’, nrow=length(unique(data[2, -1])),
ncol=1)
colnames(curr.data$types) = "color"
rownames(curr.data$types) = unique(data[2, -1])
for(i in 1:nrow(curr.data$types)) {
curr.type = rownames(curr.data$types)[i]
index = which(types == curr.type)
curr.data$types[i,1] = colors[index]
}
print(curr.data)
return(curr.data)
}
As an example, we next show the R code used to import the data for one of
the patients (RMH004) from the study.
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> library("TRONCO")
> library(RColorBrewer)
> colors = c(brewer.pal(6, "Set2"), "firebrick4", "dodgerblue4")
> types = c("Merged", "Frame Shift", "Splice site", "SNV",
> "Stop codon", "Disrupts start codon", "Gain",
> "Loss")
> rmh004.mut = import.sample("RMH004.csv")
$genotypes
G1 G2 G3 G4 G5 G6
R3 1 1 0 0 0 0
VT 1 0 0 1 0 0
R10 1 0 0 0 1 0
R4 1 0 1 0 1 0
R2 1 0 1 0 1 1
R8 1 0 1 0 1 0
X 0 0 0 0 0 0
$annotations
type event
G1 "Frame Shift" "VHL"
G2 "SNV" "SMARCA4"
G3 "Merged" "PBRM1(FS)/ATM(SC)"
G4 "Merged" "PBRM1(FS)/ARID1A(SNV)"
G5 "Frame Shift" "PTEN"
G6 "Merged" "MSH6"
$types
color
Frame Shift "#FC8D62"
SNV "#E78AC3"
Merged "#66C2A5"
Now we load the CNAs and trim any event with no observations
> rmh004.CNA = import.sample("RMH004G.csv")
$genotypes
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11
VT 0 0 1 0 0 0 0 0 1 0 0
R2 1 0 1 1 0 0 1 0 1 1 0
R3 0 0 1 0 0 0 0 0 1 0 0
R4 1 0 1 1 0 0 1 0 1 1 1
R8 1 1 1 1 0 1 1 0 1 1 0
R10 0 0 1 0 0 0 0 0 1 0 0
X 0 0 0 0 0 0 0 0 0 0 0
$annotations
type event
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G1 "Gain" "1q25.1"
G2 "Gain" "2q14.3"
G3 "Gain" "5q35.3"
G4 "Gain" "7q22.3"
G5 "Gain" "8q24.21"
G6 "Gain" "12p11.21"
G7 "Gain" "20q13.33"
G8 "Loss" "1p36.11"
G9 "Loss" "3p25.3"
G10 "Merged" "4q34.3-/8p23.2-/9p21.3-/14q31.1-"
G11 "Loss" "6q22.33"
$types
color
Gain "firebrick4"
Loss "dodgerblue4"
Merged "#66C2A5"
> rmh004.CNA = trim(rmh004.CNA)
We use the intersect function of TRONCO to merge mutations profile with
CNAs
> rmh004.data = intersect.datasets(rmh004.CNA, rmh004.mut,
> intersect.genomes = F)
*** Binding events for 2 datasets.
*** Intersect dataset [ intersect.genomes = FALSE ]
x y result
Samples 7 7 7
Genes 9 6 15
The obtained TRONCO object has then been further edited in order to
detect and handle genes with the same mutational profiles. We have to process
these data as some alterations have the same genomic profile e.g., 5q35.3 amp,
VHL fs and 3p25.3 loss. We get a report of these events with the function
consolidate.data.
> duplicated.events = consolidate.data(rmh004.data, T)
Indistinguishable events:
type event
G1 "Gain" "1q25.1"
G4 "Gain" "7q22.3"
G6 "Gain" "20q13.33"
G8 "Merged" "4q34.3-/8p23.2-/9p21.3-/14q31.1-"
G12 "Merged" "PBRM1(FS)/ATM(SC)"
Total number of events for these genes: 5
9
Indistinguishable events:
type event
G2 "Gain" "2q14.3"
G5 "Gain" "12p11.21"
Total number of events for these genes: 2
Indistinguishable events:
type event
G3 "Gain" "5q35.3"
G7 "Loss" "3p25.3"
G10 "Frame Shift" "VHL"
Total number of events for these genes: 3
We use merge.events to merge the indistinguishable events
> rmh004.data = merge.events(rmh004.data,
> "G1", "G4", "G6", "G8", "G12",
> new.event = ’1q 7q 20q 4q .. PBRM1fs ATMsc’,
> new.type = ’Merged’,
> event.color = as.colors(rmh004.data)[’Merged’])
*** Binding events for 2 datasets.
Then we re-check the IDs of the events as data were edited in the previous
step
> duplicated.events = consolidate.data(rmh004.data, T)
Indistinguishable events:
type event
G1 "Gain" "2q14.3"
G3 "Gain" "12p11.21"
Total number of events for these genes: 2
Indistinguishable events:
type event
G2 "Gain" "5q35.3"
G4 "Loss" "3p25.3"
G6 "Frame Shift" "VHL"
Total number of events for these genes: 3
> rmh004.data = merge.events(rmh004.data,
> "G1", "G3",
> new.event = ’2q 12p’,
> new.type = ’Merged’,
> event.color = as.colors(rmh004.data)[’Merged’])
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*** Binding events for 2 datasets.
> duplicated.events = consolidate.data(rmh004.data, T)
Indistinguishable events:
type event
G1 "Gain" "5q35.3"
G2 "Loss" "3p25.3"
G4 "Frame Shift" "VHL"
Total number of events for these genes: 3
> rmh004.data = merge.events(rmh004.data,
> "G1", "G2", "G4",
> new.event = ’5q 3p VHL fs’,
> new.type = ’Merged’,
> event.color = as.colors(rmh004.data)[’Merged’])
*** Binding events for 2 datasets.
The data are not yet ready for the subsequent analysis
> consolidate.data(rmh004.data, T)
$indistinguishable
list()
$zeroes
list()
$ones
list()
Besides quantification of intra-tumor heterogeneity, in their work Gerlinger
et al. found that loss of the 3p arm and alterations of the Von Hippel-Lindau
tumor suppressor gene VHL are the only events ubiquitous among their patients.
In Figure 2 we show the clonal evolution estimated for one of those patients,
RMH004, computed with CAPRESE (shrinkage coefficient λ = 0.5, time < 1
sec) from the Bernoulli 0/1 profiles provided in Supplementary Table 3 and
Figure 4 of the reference paper, with non-parametric bootstrap confidence (time
< 1 sec).
> rmh004.data = tronco.caprese(rmh004.data)
*** Checking input events.
*** Inferring a progression model with the following settings.
Dataset size: n = 7, m = 8.
Algorithm: CAPRESE with shrinkage coefficient: 0.5.
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The reconstruction has been successfully completed in 00h:00m:00s
> rmh004.data = tronco.bootstrap(rmh004.data)
Executing now the bootstrap procedure, this may take a long time...
Expected completion in approx. 00h:00m:00s
Performed non-parametric bootstrap with 100 resampling and 0.5
as shrinkage parameter.
This model may be compared to the one inferred by processing the region-
specific VAF with a max-mini optimization of most parsimonious evolutionary
trees, and performing selection-by-consensus when multiple optimal solutions
exist - Supplementary Figure 9 of the reference paper. CAPRESE requires no
arbitrarily defined curation criteria to select the optimal tree, as it constructively
searches for a solution which, in this case, is analogous in suggesting parallel
evolution of subclones via deregulation of the SWI /SNF chromatin-remodeling
complex – i.e., as may be noted from multiple clones with distinct PBMR1
mutations.
Moreover, as a further proof of concept, we now consider the somatic muta-
tions made available for two more patients, i.e., EV 002 and EV 007, once again
as Bernoulli 0/1 profiles provided in Supplementary Table 3 and Figure 4 of the
main study, of which the oncoprints follow in figure 3.
> oncoprint(example1.ev002,
> title="Phylogeny inference -
> Multiple biopses of patient EV002 (Gerlinger at al.)")
*** Oncoprint for "Phylogeny inference -
Multiple biopses of patient EV002 (Gerlinger at al.)"
with attributes: stage=FALSE, hits=TRUE
Sorting samples ordering to enhance exclusivity patterns.
Setting automatic row font (exponential scaling): 13.6
> oncoprint(example2.ev007,
> title="Phylogeny inference -
> Multiple biopses of patient EV007 (Gerlinger at al.)")
*** Oncoprint for "Phylogeny inference -
Multiple biopses of patient EV007 (Gerlinger at al.)"
with attributes: stage=FALSE, hits=TRUE
Sorting samples ordering to enhance exclusivity patterns.
Setting automatic row font (exponential scaling): 13.8
The inference on such patients is performed again with CAPRESE algorithm
with shrinkage coefficient 0.5 (optimal value), and requires less than 1 second
in a standard laptop; non-parametric bootstrap confidence is subsequently esti-
mated.
We finally show the reconstructions (figure 4) of the above patients and we
observe that once again CAPRESE captures the same clonal evolution depicted
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Figure 2: (A) With data provided by Gerlinger et al., we infer a patient-specific
clonal evolution from 6 biopsies of a clear cell renal carcinoma (5 primary tu-
mor, 1 from the thrombus in the renal vein, V T ). Validated non-synonymous
mutations are selected for VHL, SMARCA4, PTEN, PBMR1, ARID1A, ATM
and MSH6 genes. CNAs are detected on 12 chromosomes. For this patient,
both region-specific allele frequencies and Bernoulli profiles are provided. Thus,
we can extract a clonal tree, signature and diffusion of each clone, by the unsu-
pervised CAPRESE algorithm. (B) The unsupervised model inferred by CAP-
RESE predicts an analogous clonal expansion observed in the main paper, and
extracted with most parsimonious phylogeny tree reconstruction from allelic
frequencies, and hand-curated for selection of the optimal model. For simplic-
ity, we show only expansion of the sub-clones harbouring PTEN ’s frame shift
mutation.
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Phylogeny inference − Multiple biopses of patient EV002
88% VHL(FS)/PBRM1(FS)
75% SETD2
38% PTEN
12% SETD2(SNV)/TP53(SNV)
12% PTEN
none
Merged
Frame Shift
Splice site
SNV
Phylogeny inference − Multiple biopses of patient EV007
88% VHL(FS)/BAP1(SNV)
25% SETD2
25% SETD2(SNV)/TP53(SC)
12% PIK3CA
none
Merged
Stop codon
SNV
Figure 3: Oncoprint showing the genomic profiles of patients EV 002 (top) and
EV 007 (bottom) from the study of Gerlinger et al., Nat Gen 46, 2014.
in the reference paper.
> tronco.plot(example1.ev002,scale.nodes=T,confidence=c("npb"),
> legend.pos="",label.edge.size=22,title="Inference by CAPRESE -
> Multiple biopses of patient EV002 (Gerlinger at al.)")
*** Expanding hypotheses syntax as graph nodes:
*** Rendering graphics
Nodes with no incoming/outgoing edges will not be displayed.
Set automatic fontsize scaling for node labels: 17.5622483502636
Adding confidence information: npb
RGraphviz object prepared.
Plotting graph and adding legends.
> tronco.plot(example2.ev007,scale.nodes=T,confidence=c("npb"),
> legend.pos="",label.edge.size=13,title="Inference by CAPRESE -
> Multiple biopses of patient EV007 (Gerlinger at al.)")
*** Expanding hypotheses syntax as graph nodes:
*** Rendering graphics
Nodes with no incoming/outgoing edges will not be displayed.
Set automatic fontsize scaling for node labels: 18.4548225555204
Adding confidence information: npb
RGraphviz object prepared.
Plotting graph and adding legends.
2.3 Atypical Chronic Myeloid Leukemia (aCML)
We now finally consider the data from Piazza et al., Nat Gen 45, 2013 as a
proof of usage of both CAPRESE and CAPRI algorithms on ensamble level
data. Figure 5 shows the data used as inputs for both the two algorithms.
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Inference by CAPRESE − Multiple biopses of patient EV002
VHL(FS)/PBRM1(FS)
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12% (1)
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38% (3) 12% (1)
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Inference by CAPRESE - Multiple biopses of patient EV007
VHL(FS)/BAP1(SNV)
88% (7)
SETD2
25% (2)
SETD2/TP53
25% (2)
PIK3CA
12% (1)
0.54 0.48
0.37
Events type
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Stop codon
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Figure 4: Reconstructions by CAPRESE for patients EV 002 (left) and EV 007
(right) from the study of Gerlinger et al., Nat Gen 46, 2014.
> require("TRONCO")
> data(aCML)
> aCML.alterations = events.selection(as.alterations(aCML),
+ filter.freq=.05, filter.in.names=c(’KRAS’, ’NRAS’, ’IDH1’,
+ ’IDH2’, ’TET2’, ’SF3B1’, ’ASXL1’))
*** Aggregating events of type(s) {Ins/Del, Missense point, Nonsense
Ins/Del, Nonsense point}
in a unique event with label "Alteration".
Dropping event types Ins/Del, Missense point, Nonsense Ins/Del,
Nonsense point for 23 genes.
*** Binding events for 2 datasets.
*** Events selection: #events=23, #types=1 Filters freq|in|out =
{TRUE, TRUE, FALSE}
Minimum event frequency: 0.05 (3 alterations out of 64 samples).
Selected 7 events.
[filter.in] Genes hold: KRAS, NRAS, IDH1, IDH2, TET2 ... [6/7 found].
Selected 10 events, returning.
> aCML.alterations = change.color(aCML.alterations,
> type="Alteration", new.color="khaki4")
> oncoprint(aCML.alterations)
*** Oncoprint for ""
with attributes: stage=FALSE, hits=TRUE
Sorting samples ordering to enhance exclusivity patterns.
Setting automatic row font (exponential scaling): 12.3
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Moreover, we gave as a further input to CAPRI algorithm patterns of mutual
exclusivity among genes: TET2 and IDH2, ASXL1 and SF3B1, NRAS and
KRAS.
> aCML.alterations.hypo = hypothesis.add(aCML.alterations,
> ’TET2 xor IDH2’, XOR(’TET2’,’IDH2’))
> aCML.alterations.hypo = hypothesis.add(aCML.alterations.hypo,
> ’ASXL1 xor SF3B1’, XOR(’ASXL1’,’SF3B1’))
> aCML.alterations.hypo = hypothesis.add(aCML.alterations.hypo,
> ’NRAS xor KRAS’, XOR(’NRAS’,’KRAS’))
atypical Chronic Myeloid Leukemia (aCML)
25% TET2
22% ASXL1
22% SETBP1
16% EZH2
11% CSF3R
8% NRAS
6% CBL
5% IDH2
2% KRAS
2% SF3B1
hits hits
4
0
none
Alteration
64 samples
10 events
10 genes
0 patterns
Figure 5: Oncoprint showing the genomic profiles of 64 aCML patients from the
study of Piazza et al., Nat Gen 45, 2013.
We conclude by showing the results of the inference from both CAPRESE
and CAPRI algorithms in figure 6.
> caprese = tronco.caprese(aCML.alterations)
*** Checking input events.
*** Inferring a progression model with the following settings.
Dataset size: n = 64, m = 10.
Algorithm: CAPRESE with shrinkage coefficient: 0.5.
The reconstruction has been successfully completed in 00h:00m:00s
> capri = tronco.capri(aCML.alterations.hypo)
*** Checking input events.
*** Inferring a progression model with the following settings.
Dataset size: n = 64, m = 13.
Algorithm: CAPRI with "bic, aic" regularization and
"hc" likelihood-fit strategy.
Random seed: NULL.
Bootstrap iterations (Wilcoxon): 100.
exhaustive bootstrap: TRUE.
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p-value: 0.05.
minimum bootstrapped scores: 3.
*** Bootstraping selective advantage scores (prima facie).
Evaluating "temporal priority" (Wilcoxon, p-value 0.05)
Evaluating "probability raising" (Wilcoxon, p-value 0.05)
*** Loop detection found loops to break.
Removed 5 edges out of 30 (17%)
*** Performing likelihood-fit with regularization bic.
*** Performing likelihood-fit with regularization aic.
The reconstruction has been successfully completed in 00h:00m:02s
There were 27 warnings (use warnings() to see them)
> tronco.plot(caprese, scale.nodes=F,
> title="aCML - Inference by CAPRESE")
*** Expanding hypotheses syntax as graph nodes:
*** Rendering graphics
Nodes with no incoming/outgoing edges will not be displayed.
Set automatic fontsize scaling for node labels: 15.2111016906551
Set automatic fontsize for edge labels: 7.60555084532756
Plotting graph and adding legends.
> tronco.plot(capri, scale.nodes=F,
> title="aCML - Inference by CAPRI")
*** Expanding hypotheses syntax as graph nodes:
*** Rendering graphics
Nodes with no incoming/outgoing edges will not be displayed.
Set automatic fontsize scaling for node labels: 16.2163594037787
Set automatic fontsize for edge labels: 8.10817970188937
Plotting graph and adding legends.
Figure 6: Inference by CAPRESE (left) and CAPRI (right) applied on the
genomic profiles of 64 aCML patients from the study of Piazza et al., Nat Gen
45, 2013.
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